Search results for "malignant"

showing 10 items of 283 documents

The role of microRNAs in oral lichenoid disorders. Systematic review

2017

Background: Certain changes in the microRNA expression are considered to be associated with chronic inflammatory processes and with the malignant transformation of oral potentially malignant disorders. The purpose of this systematic review is to update the existing data on the aberrant microRNA expression profiles identified in oral lichenoid disease (OLD).

0301 basic medicineMEDLINEReviewDiseaseBioinformaticsMalignant transformation03 medical and health sciencesmicroRNAHumansMedicineNon-coding RNAGeneral DentistryUNESCO:CIENCIAS MÉDICASOral Medicine and Pathologybusiness.industryMouth -- DiseasesMicroRNA Expression ProfileSmall interfering RNAmedicine.diseaseMicroRNAsstomatognathic diseases030104 developmental biologyOtorhinolaryngologySurgeryOral lichen planusbusinessLichen Planus Oral
researchProduct

Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.

2018

0301 basic medicineMesotheliomaLung NeoplasmsPleural NeoplasmsPemetrexed03 medical and health sciences0302 clinical medicineGeneticsmedicineBiomarkers TumorHumansMesotheliomaProton-coupled folate transporterPharmacologybusiness.industryPleural mesotheliomaMesothelioma Malignantmedicine.diseasechemoresistance mesothelioma PCFT pemetrexed030104 developmental biologyPemetrexedDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchMolecular MedicineBiomarker (medicine)businessProton-Coupled Folate Transportermedicine.drugPharmacogenomics
researchProduct

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

2016

Abstract As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non–small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 remains elusive. Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically engineered mouse models of lung adenocarcinoma. Deregulated EZH2 silences normal developmental pathways, leading to epigenetic transformation independent of canonical growth factor pathway activation. As such, tumors feature a transcrip…

0301 basic medicineModels MolecularLung Neoplasmsmedicine.medical_treatmentMolecular ConformationGene ExpressionAntineoplastic Agentsmacromolecular substancesBiologymedicine.disease_causeArticleMalignant transformationTargeted therapy03 medical and health sciencesMiceStructure-Activity RelationshipCell Line TumormedicineAnimalsHumansEnhancer of Zeste Homolog 2 ProteinMolecular Targeted TherapyLung cancerPromoter Regions GeneticGene Expression ProfilingEZH2Cancermedicine.diseaseMagnetic Resonance ImagingXenograft Model Antitumor AssaysChromatinrespiratory tract diseasesGene Expression Regulation NeoplasticDisease Models Animal030104 developmental biologyCell Transformation NeoplasticEnhancer Elements GeneticOncologyDrug DesignCancer researchAdenocarcinomaKRASEpigenetic therapyCancer discovery
researchProduct

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

2020

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a signifi…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentClinical BiochemistryKaplan-Meier EstimateDisease-Free SurvivalDrug Administration ScheduleNO03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineMalignant pleural effusionHumansimmunotherapy; malignant pleural effusion; nivolumab; non-small-cell lung cancerIn patientmalignant pleural effusionLung cancerImmune Checkpoint InhibitorsRetrospective StudiesPharmacologynivolumabbusiness.industryBrain NeoplasmsLiver NeoplasmsImmunotherapymedicine.diseasePrognosisPleural Effusion Malignantrespiratory tract diseases030104 developmental biologyTreatment Outcomenon-small-cell lung cancer030220 oncology & carcinogenesisFemalesense organsNon small cellimmunotherapyNivolumabbusiness
researchProduct

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

2016

Abstract: Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleura with a poor prognosis. The most active first-line regimens are platinum compounds and pemetrexed. There is no standard second-line treatment in MPM. Advances in the understanding of tumor molecular biology have led to the development of several targeted treatments, which have been evaluated in clinical trials. Unfortunately none of the explored targeted treatments can currently be recommended as routine treatment in MPM. We reviewed the biological pathways involved in MPM, the clinical trials about targeted therapy, and possible related mechanisms of resistance. We suggest that specific genetic markers are n…

0301 basic medicineOncologyDrugMesotheliomamedicine.medical_specialtyPathologyLung NeoplasmsSettore MED/06 - Oncologia Medicamedia_common.quotation_subjectmedicine.medical_treatmentPleural NeoplasmsResistanceAntineoplastic AgentsTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsHumansMesotheliomaMolecular Targeted Therapymedia_commonPleural mesotheliomabusiness.industryPlatinum compoundsMesothelioma MalignantHematologymedicine.diseaseClinical trial030104 developmental biologyPemetrexedOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationPleuraMesothelioma; Pleura; Resistance; Targeted therapyMolecular ProfileHuman medicinebusinessmedicine.drug
researchProduct

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

2016

// Aurelie Bertaut 1 , Caroline Truntzer 2 , Rachid Madkouri 3 , Coureche Guillaume Kaderbhai 4 , Valentin Derangere 5 , Julie Vincent 4 , Bruno Chauffert 6 , Marie Helene Aubriot-Lorton 7 , Wahlid Farah 3 , Klaus Luc Mourier 3 , Romain Boidot 5,8 and Francois Ghiringhelli 4,5,8,9 1 Biostatistics unit Georges Francois Leclerc Cancer Center, Dijon, France 2 CLIPP, Research Center, University of Burgundy, Dijon, France 3 Department of Neurosurgery, CHU, Dijon, France 4 Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France 5 Platform of Transfer in Cancer Biology Genetic and histology, Georges Francois Leclerc Cancer Center, Dijon, France 6 Department of Medical…

0301 basic medicineOncologyMaleVascular Endothelial Growth Factor Agenetic structuresNeutrophilsmedicine.medical_treatmentAngiogenesis InhibitorsBiomarkers Pharmacological[ SDV.CAN ] Life Sciences [q-bio]/CancerLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorEndothelial Growth-Factorprognostic factorNeoadjuvant therapyRandomized Controlled Trials as TopicNeovascularization PathologicBrain NeoplasmsColony-Stimulating FactorAge FactorsChemoradiotherapyMiddle AgedPrognosisNeoadjuvant Therapy3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisTo-Lymphocyte RatioAbsolute neutrophil countFemalemedicine.drugmedicine.medical_specialtyBevacizumabMalignant Glioma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPretreatment NeutrophilKarnofsky Performance StatusSingle-Agent BevacizumabRetrospective StudiesNewly-Diagnosed GlioblastomaRecurrent Glioblastomabusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyGene Expression ProfilingglioblastomaCancerRetrospective cohort studyLomustinemedicine.diseasePhase-Ii Trialeye diseasesSurgeryIrinotecan030104 developmental biologyprognosistic factorBrain-Tumorssense organsClinical Research PaperNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

A catch-22: Interleukin-22 and cancer.

2017

Barrier surfaces of multicellular organisms are in constant contact with the environment and infractions to the integrity of epithelial surfaces is likely a frequent event. Interestingly, components of the immune system, that can be activated by environmental compounds such as the microbiota or nutrients, are interspersed among epithelial cells or directly underlie the epithelium. It is now appreciated that immune cells continuously receive and integrate signals from the environment. Curiously, such continuous reception of stimulation does not normally trigger an inflammatory response but mediators produced by immune cells in response to such signals seem to rather promote barrier integrity…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentImmunologyBiologyPolymorphism Single NucleotideEpitheliumMalignant transformationTight JunctionsInterleukin 2203 medical and health sciences0302 clinical medicineImmune systemInternal medicineNeoplasmsmedicineImmunology and AllergyAnimalsHumansLymphocytesIntestinal MucosaReceptorWound HealingInterleukinsMicrobiotaInnate lymphoid cellEpithelial CellsEpitheliumImmunity InnateCell biology030104 developmental biologyCytokinemedicine.anatomical_structureCell Transformation NeoplasticWound healing030215 immunologyEuropean journal of immunology
researchProduct

Comparative Evaluation of role of Lysyl oxidase gene (LOXG473A) expression in pathogenesis and malignant transformation of Oral Submucous Fibrosis.

2019

Background Identification and comparison of gene expression of Lysyl oxidase (LOX) in oral submucous fibrosis and controls and to determine its role in Pathogenesis of Oral submucous fibrosis. Material and Methods Of total sample size (n=127), the whole blood sample were collected from case and control group in citrate vial. It is centrifused and stored at -800C. We collected and isolated RNA from blood of case group (n=127) and age and sex matched control group (n=127) recruited on the basis of inclusion criteria. The cDNA was prepared for 127 samples which were processed for gene expression of Lysyl oxidase (LOX) in relation to housekeeping genes (Beta actin and 18srRNA) and its role in p…

0301 basic medicineOral Medicine and Pathologyintegumentary systemResearchLysyl oxidaseBiologymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Molecular biologyMalignant transformationHousekeeping genePathogenesis03 medical and health sciencesenzymes and coenzymes (carbohydrates)030104 developmental biology0302 clinical medicineOral submucous fibrosis030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASGene expressionmedicineBeta-actinGeneral DentistryGeneJournal of clinical and experimental dentistry
researchProduct

Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma

2017

Background Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is specifically expressed in lymphatic endothelial cells. Studies have shown that assessment of podoplanin expression in the epithelial cells can be used to predict the malignant transformation of potentially malignant disorders and the metastatic tendency of primary head and neck squamous cell carcinoma. The aim of our study was to compare the expression of podoplanin in oral leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma with that in normal buccal mucosa by immunohistochemical methods. Material and methods Immunohistochemical expression of podoplanin was analyzed in 20 cases each of or…

0301 basic medicinePathologymedicine.medical_specialtymedicine.drug_classgovernment.form_of_governmentMonoclonal antibodyMalignant transformation03 medical and health sciences0302 clinical medicineDownregulation and upregulationmedicineGeneral DentistryOral Medicine and Pathologybusiness.industryResearchmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Head and neck squamous-cell carcinomaLymphatic Endotheliumstomatognathic diseases030104 developmental biologyOral submucous fibrosisPodoplanin030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASgovernmentImmunohistochemistrybusiness
researchProduct

Sex-Specific Genetic Effects Associated with Pigmentation, Sensitivity to Sunlight, And Melanoma in a Population of Spanish Origin

2016

Background Human pigmentation is a polygenic quantitative trait with high heritability. In addition to genetic factors, it has been shown that pigmentation can be modulated by oestrogens and androgens via up- or down-regulation of melanin synthesis. Our aim was to identify possible sex differences in pigmentation phenotype as well as in melanoma association in a melanoma case-control population of Spanish origin. Methods Five hundred and ninety-nine females (316 melanoma cases and 283 controls) and 458 males (234 melanoma cases and 224 controls) were analysed. We genotyped 363 polymorphisms (single nucleotide polymorphisms (SNPs)) from 65 pigmentation gene regions. Results When samples were…

0301 basic medicinePopulationGenome-wide association studyBiologyQuantitative trait locussusceptibilityGender Studies03 medical and health sciences0302 clinical medicineEndocrinologymedicinesex polymorphismssexpigmentationeducationriskGeneticseducation.field_of_studyvariantsskin cancerMelanomaResearchdeterminantsHeritabilitymedicine.diseasePhenotypeeyecolor030104 developmental biology030220 oncology & carcinogenesisSpanish Origingenome-wide associationskin pigmentationsense organsSkin cancerUV sensitivitypolymorphismsmalignant-melanomaeuropeans
researchProduct